Vicarious Surgical's Cash Runway Limited to Q2 Amid Q1 Loss, No Revenue
summarizeSummary
Vicarious Surgical Inc. reported a Q1 2026 net loss of $(7.3M) and diluted EPS of $(1.03), with no operating revenue for the period. While the net loss improved significantly year-over-year, the company explicitly stated that its cash runway is limited into Q2 2026 absent new financing. This critical liquidity constraint, coupled with the ongoing lack of revenue and the prior NYSE delisting (as noted in the recent 10-K), reinforces substantial doubt about the company's ability to continue as a going concern. Traders will be closely watching for any announcements regarding new financing or significant progress towards FDA authorization for its surgical robot, as the current financial position indicates an urgent need for capital.
At the time of this announcement, RBOT was trading at $0.55 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $0.27 to $13.75. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.